ReviewRheumatology (Oxford, England)2019
Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.
Review in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives.Life (Basel, Switzerland) · 2026Review
- Review
- MMP-7 as a non-invasive biomarker in interstitial lung diseases and other chronic respiratory diseases: a narrative review.Frontiers in medicine · 2026Review
- Associations of serum CA 15-3 with interstitial lung disease, PM/Scl100 antibodies and other disease characteristics in systemic sclerosis.Scientific reports · 2025Article
- Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease.Current treatment options in rheumatology · 2025Article
- Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease.Arthritis research & therapy · 2025Article
- Assessing Fibrosis Progression and Endothelial Dysfunction in SSc-ILD and COPD: An Integrated Biomarker and CT Densitometry Approach.Medicina (Kaunas, Lithuania) · 2025Observational
- Systemic Sclerosis with Interstitial Lung Disease: Identification of Novel Immunogenetic Markers and Ethnic Specificity in Kazakh Patients.Epidemiologia (Basel, Switzerland) · 2025Article
- Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease.Biomedicines · 2025Review
- Insights into interstitial lung disease pathogenesis.Breathe (Sheffield, England) · 2025Review
- Accelerated Type VII collagen turnover in systemic sclerosis patients, reflected by serological neo-epitope fragment biomarkers.Arthritis research & therapy · 2025Article
- Matrix metalloproteinases and their tissue inhibitors as upcoming biomarker signatures of connective tissue diseases-related interstitial lung disease: towards an earlier and accurate diagnosis.Molecular medicine (Cambridge, Mass.) · 2025Article
- Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients.Respiratory research · 2025Article
- Evaluating the role of active TGF-β1 as inflammatory biomarker in Kashmiri (North-Indian) patients with systemic sclerosis: a case-control study.Advances in rheumatology (London, England) · 2024Article
- Long Term Evaluation of Quantitative Cumulative Irradiation in Patients Suffering from ILDs.Diagnostics (Basel, Switzerland) · 2024Article
- Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention.Life (Basel, Switzerland) · 2024Review
- Prevalence of hybrid TLR4Frontiers in immunology · 2024Article
- Cytokine correlations in childhood-onset rheumatic diseases with pulmonary involvement.Frontiers in pediatrics · 2024Article
- Reproducibility of pulmonary function tests in patients with systemic sclerosis.Scientific reports · 2023Observational
- [Characteristics of patients with systemic sclerosis who develop interstitial lung disease].Revista medica del Instituto Mexicano del Seguro Social · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive immunosuppression it should not be given to stable or non-progressing disease. The correct identification of disease with high risk of progression remains a challenge for early therapeutic intervention, and biomarkers remain urgently needed. In fact, eight categories of biomarkers have been identified and classified according to the different biological pathways involved. The purpose of this article is to describe the main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-interstitial lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.